Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma

Leuk Lymphoma. 2017 Mar;58(3):752-753. doi: 10.1080/10428194.2016.1207764. Epub 2016 Jul 14.

Authors

Natalie Galanina¹, Jagoda Jasielec², David Peace³, Sonali M Smith¹, Chadi Nabhan¹

Affiliations

¹ a The University of Chicago Medical Center , Chicago , IL , USA.
² b North Shore University Health System , Chicago , IL , USA.
³ c The University of Illinois at Chicago , Chicago , IL , USA.

PMID: 27415580
DOI: 10.1080/10428194.2016.1207764

No abstract available

Publication types

Clinical Trial, Phase II
Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Drug Resistance, Neoplasm
Female
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / pathology*
Male
Middle Aged
Neoplasm Staging
Recurrence
Retreatment
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
ofatumumab